The CEO of FibroBiologics describes the idea of using fibroblasts rather than stem cells for regenerative medicine and chronic diseases

blonca9
Jun 6, 2024
1 min read

Pete O'Heeron makes the case for fibroblasts and describes FibroBiologics's clincal MS program and upcoming ones for diabetic wound care and degenerative disc disease.

Recent Posts

See All

As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact

Mount Sinai has embraced AI as a drug discovery tool by launching this month its new AI Small Molecule Drug Discovery Center - Professor Avner Schlessinger tells us why

Jones Healthcare & Technology Innovation Conference: Jones Research analysts Soumit Roy and Justin Walsh share their take on biotech and comment on companies they cover

The CEO of FibroBiologics describes the idea of using fibroblasts rather than stem cells for regenerative medicine and chronic diseases

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight